Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)12.81bn
- Net income in JPY56.80m
- Incorporated2006
- Employees141.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mochida Pharmaceutical Co Ltd | 109.37bn | 9.58bn | 135.74bn | 1.54k | 13.37 | 0.9755 | 11.10 | 1.24 | 252.77 | 252.77 | 2,899.75 | 3,464.88 | 0.678 | 2.24 | 3.58 | 70,835,500.00 | 5.94 | 5.22 | 7.12 | 6.40 | 53.99 | 51.57 | 8.75 | 7.76 | 3.62 | -- | 0.00 | 40.56 | 6.98 | 2.51 | 23.08 | 4.39 | 21.99 | 3.04 |
| KAKEN PHARMACEUTICAL CO., LTD. | 73.90bn | 8.45bn | 166.76bn | 1.16k | 16.14 | 0.9708 | 23.35 | 2.26 | 224.91 | 224.91 | 1,962.43 | 3,739.38 | 0.4406 | 2.00 | 2.84 | 63,487,110.00 | 5.04 | 10.15 | 5.77 | 12.06 | 54.29 | 56.09 | 11.44 | 18.28 | 4.98 | -- | 0.0266 | 37.00 | 1.41 | -5.61 | -28.77 | -15.39 | 6.71 | 0.00 |
| Sawai Group Holdings Co Ltd | 192.93bn | -31.03bn | 170.35bn | 2.97k | -- | 0.8422 | -- | 0.883 | -709.06 | -709.06 | 4,400.23 | 4,618.62 | 0.4943 | 1.48 | 2.88 | 65,002,360.00 | -11.39 | 1.25 | -15.97 | 1.70 | 31.76 | 38.97 | -23.05 | 2.46 | 1.24 | -155.68 | 0.2585 | 76.82 | 3.52 | 7.92 | -329.08 | -- | 4.38 | 0.00 |
| Sosei Group Corporation | 22.76bn | -383.00m | 197.11bn | 198.00 | -- | 3.54 | 211.04 | 8.66 | -4.70 | -4.70 | 278.03 | 679.92 | 0.2473 | -- | 19.92 | 114,964,600.00 | -0.416 | -- | -0.4321 | -- | 95.45 | -- | -1.68 | -- | -- | 2.57 | 0.3475 | -- | 100.32 | -- | -31.24 | -- | -- | -- |
| JCR Pharmaceuticals Co Ltd | 37.51bn | 5.15bn | 207.24bn | 816.00 | 38.73 | 3.83 | 51.08 | 5.53 | 41.26 | 41.26 | 301.20 | 417.04 | 0.4052 | 0.6419 | 2.64 | 45,965,690.00 | 5.59 | 11.47 | 9.33 | 16.27 | 71.92 | 73.58 | 13.80 | 20.62 | 0.8526 | -- | 0.2571 | 22.46 | 69.79 | 23.08 | 110.49 | 50.75 | 48.86 | 29.46 |
| TAKARA BIO INC. | 68.74bn | 18.38bn | 207.84bn | 1.67k | 11.31 | 1.95 | 9.11 | 3.02 | 152.62 | 152.62 | 570.82 | 886.08 | 0.6115 | 1.21 | 4.59 | 41,257,500.00 | 16.39 | 9.94 | 18.79 | 11.16 | 69.46 | 65.37 | 26.81 | 18.17 | 4.31 | 37.63 | 0.00 | 21.03 | 46.90 | 18.17 | 107.91 | 71.14 | 52.57 | 52.51 |
| Tsumura & Co | 138.24bn | 19.32bn | 208.09bn | 3.92k | 10.73 | 0.8034 | 6.77 | 1.51 | 252.68 | 252.68 | 1,807.88 | 3,374.39 | 0.3739 | 0.7393 | 2.39 | 35,256,310.00 | 5.53 | 5.19 | 6.65 | 6.28 | 49.65 | 55.78 | 14.78 | 12.78 | 3.89 | -- | 0.2218 | 31.45 | 11.28 | 2.42 | 22.85 | 8.57 | 4.99 | 0.00 |
| Peptidream Inc | 12.81bn | 56.80m | 259.76bn | 141.00 | 4,629.72 | 10.60 | 162.37 | 20.28 | 0.4316 | 0.4316 | 98.66 | 188.50 | 0.3237 | 3.97 | 3.15 | -- | 0.1435 | -- | 0.1626 | -- | 50.04 | -- | 0.4434 | -- | 1.92 | -- | 0.4629 | -- | -19.79 | -- | -18.93 | -- | -- | -- |
| Hisamitsu Pharmaceutical Co Inc | 125.41bn | 12.96bn | 333.42bn | 2.78k | 24.11 | 1.15 | 18.72 | 2.66 | 162.40 | 162.40 | 1,571.35 | 3,393.17 | 0.3914 | 2.88 | 3.58 | 45,047,060.00 | 4.14 | 5.15 | 4.81 | 5.83 | 56.67 | 61.16 | 10.57 | 11.52 | 3.86 | -- | 0.0045 | 44.97 | 4.96 | -3.81 | 4.41 | -13.89 | 5.56 | 0.6061 |
| Sumitomo Pharma Co Ltd | 588.23bn | -8.45bn | 342.59bn | 6.99k | -- | 0.5386 | 22.78 | 0.5824 | -21.27 | -21.27 | 1,480.56 | 1,598.70 | 0.441 | 1.94 | 3.86 | 84,188,920.00 | -2.04 | 4.10 | -2.78 | 5.97 | 69.56 | 73.85 | -4.63 | 8.67 | 1.58 | -- | 0.2635 | 21.77 | 8.54 | 6.52 | 0.3451 | 12.49 | 0.052 | 9.24 |
| Santen Pharmaceutical Co Ltd | 266.41bn | -9.14bn | 383.17bn | 4.32k | -- | 1.23 | 44.10 | 1.44 | -26.56 | -26.56 | 675.20 | 799.46 | 0.6291 | 2.84 | 3.06 | 61,741,140.00 | -2.14 | 6.25 | -2.59 | 7.56 | 57.70 | 60.55 | -3.41 | 10.30 | 2.36 | -- | 0.1688 | 43.85 | 6.67 | 5.99 | 192.38 | 4.60 | 30.42 | 4.24 |
Data as of Feb 06 2023. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY
28.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Taiyo Pacific Partners LPas of 29 Aug 2022 | 9.36m | 7.20% |
| JOHCM (Singapore) Pte Ltd.as of 24 Aug 2021 | 5.75m | 4.42% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Dec 2022 | 5.41m | 4.16% |
| Nomura Asset Management Co., Ltd.as of 30 Dec 2022 | 3.13m | 2.41% |
| Baillie Gifford & Co.as of 31 Dec 2022 | 3.07m | 2.36% |
| Invesco Advisers, Inc.as of 31 Dec 2022 | 3.05m | 2.35% |
| The Vanguard Group, Inc.as of 05 Jan 2023 | 2.28m | 1.75% |
| Alma Capital Investment Management SA (UK)as of 30 Jun 2022 | 1.95m | 1.50% |
| BlackRock Fund Advisorsas of 30 Nov 2021 | 1.82m | 1.40% |
| Nikko Asset Management Co., Ltd.as of 15 Dec 2022 | 1.81m | 1.40% |
More ▼
Data from 30 Sep 2019 - 31 Dec 2022Source: FactSet Research Systems Inc.
